A novel mutation of the GAA gene in a Finnish late‐onset pompe disease patient: Clinical phenotype and follow‐up with enzyme replacement therapy

No abstract is available for this paper.

• Publication year

  2009

• Venue

  Muscle and Nerve

• Publication date

  2009-07-01

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1002/mus.21291PMID 19472353
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Methods for a prompt and reliable laboratory diagnosis of Pompe disease: report from an international consensus meeting.

  2008cited by this paper
• Update of the Pompe disease mutation database with 107 sequence variants and a format for severity rating

  2008cited by this paper
• Muscle MRI findings in siblings with juvenile-onset acid maltase deficiency (Pompe disease).

  2008cited by this paper
• Recombinant human acid α-glucosidase: Major clinical benefits in infantile-onset Pompe disease

  2008cited by this paper
• Broad spectrum of Pompe disease in patients with the same c.-32-13T→G haplotype

  2007cited by this paper
• Recombinant human acid [alpha]-glucosidase: major clinical benefits in infantile-onset Pompe disease.

  2007cited by this paper
• Recombinant human acid α-glucosidase: Major clinical benefits in infantile-onset Pompe disease

  2007cited by this paper
• Late onset Pompe disease: clinical and neurophysiological spectrum of 38 patients including long-term follow-up in 18 patients.

  2007cited by this paper
• Chinese hamster ovary cell-derived recombinant human acid alpha-glucosidase in infantile-onset Pompe disease.

  2006cited by this paper
• Two new missense mutations of GAA in late onset glycogen storage disease type II.

  2006cited by this paper
• Safety and efficacy of recombinant acid alpha-glucosidase (rhGAA) in patients with classical infantile Pompe disease: results of a phase II clinical trial.

  2005cited by this paper
• Twenty‐two novel mutations in the lysosomal α‐glucosidase gene (GAA) underscore the genotype–phenotype correlation in glycogen storage disease type II

  2004cited by this paper
• Muscle MRI in adult-onset acid maltase deficiency.

  2004cited by this paper
• Long-term intravenous treatment of Pompe disease with recombinant human alpha-glucosidase from milk.

  2004cited by this paper
• Long-Term Intravenous Treatment of Pompe Disease With Recombinant Human -Glucosidase From Milk

  2004cited by this paper
• Enzyme replacement therapy in late‐onset Pompe's disease: A three‐year follow‐up

  2004cited by this paper
• Acid alpha-glucosidase deficiency (glycogenosis type II, Pompe disease).

  2002cited by this paper
• Enzyme therapy for pompe disease with recombinant human alpha-glucosidase from rabbit milk.

  2001cited by this paper
• Insights into muscle diseases gained by phosphorus magnetic resonance spectroscopy

  2000cited by this paper
• Muscle phosphorus magnetic resonance spectroscopy oxidative indices correlate with physical activity

  2000cited by this paper
• Frequent mutations in Japanese patients with acid maltase deficiency.

  2000cited by this paper
• Glycogen storage disease type II: Genetic and biochemical analysis of novel mutations in infantile patients from Turkish ancestry

  1998cited by this paper
• Glycogenosis type II: A juvenile‐specific mutation with an unusual splicing pattern and a shared mutation in African Americans

  1997cited by this paper
• The effect of a single base pair deletion (ΔT525) and a C1634T missense mutation (pro545leu) on the expression of lysosomal α-glucosidase in patients with glycogen storage disease type II

  1994cited by this paper
• Aberrant splicing in adult onset glycogen storage disease type II (GSDII): molecular identification of an IVS1 (-13T-->G) mutation in a majority of patients and a novel IVS10 (+1GT-->CT) mutation.

  1994cited by this paper
• The effect of a single base pair deletion (delta T525) and a C1634T missense mutation (pro545leu) on the expression of lysosomal alpha-glucosidase in patients with glycogen storage disease type II.

  1994cited by this paper
• The conservative substitution Asp-645-->Glu in lysosomal alpha-glucosidase affects transport and phosphorylation of the enzyme in an adult patient with glycogen-storage disease type II.

  1993cited by this paper
• Effect of hypothyroidism on phosphorus metabolism in muscle and liver: In vivo P‐31 MR spectroscopy study

  1992cited by this paper
• Identification of a Missense Mutation in an Adult-Onset Patient with Glycogenosis Type II Expressing Only One Allele

  1991cited by this paper
• Phosphorus magnetic resonance spectroscopy (31P MRS) in neuromuscular disorders

  1991cited by this paper
• Dermatomyositis: correlative MR imaging and P-31 MR spectroscopy for quantitative characterization of inflammatory disease.

  1990cited by this paper
• Cystic fibrosis in Finland: a molecular and genealogical study

  1989cited by this paper
• Phosphorus nuclear magnetic resonance of fast- and slow-twitch muscle.

  1985cited by this paper

• Pompe disease in China: clinical and molecular characteristics

  2023cites this paper
• An artificial intelligence-based approach for identifying rare disease patients using retrospective electronic health records applied for Pompe disease

  2023cites this paper
• Targeted Therapies for Metabolic Myopathies Related to Glycogen Storage and Lipid Metabolism: a Systematic Review and Steps Towards a ‘Treatabolome’

  2021cites this paper
• Carrier frequency and predicted genetic prevalence of Pompe disease based on a general population database

  2021cites this paper
• European consensus for starting and sto...e disease: a 10year experience

  2019cites this paper
• Molecular genetics of Pompe disease: a comprehensive overview.

  2019cites this paper
• Effects of Enzyme Replacement Therapy on the Respiratory and Motor Functions Among Patients with Late-Onset Pompe Disease for Long-Term

  2019cites this paper
• European consensus for starting and stopping enzyme replacement therapy in adult patients with Pompe disease: a 10-year experience

  2019cites this paper
• The effectiveness of enzyme replacement therapy for juvenile-onset Pompe disease: a systematic review

  2018cites this paper
• The effectiveness of enzyme replacement therapy for juvenile-onset Pompe disease : a systematic review

  2018cites this paper
• European consensus for starting and stopping enzyme replacement therapy in adult patients with Pompe disease: a 10‐year experience

  2017cites this paper
• Childhood Pompe disease: clinical spectrum and genotype in 31 patients

  2016cites this paper
• Search for Pompe disease among patients with undetermined myopathies

  2016cites this paper
• Screening for late-onset Pompe disease in Finland.

  2014cites this paper
• Structural studies on lysosomal proteins

  2014cites this paper
• Immune Responses and Hypercoagulation in ERT for Pompe Disease Are Mutation and rhGAA Dose Dependent

  2014cites this paper
• Heidi Repo Structural studies on lysosomal proteins

  2014cites this paper
• Enzyme replacement therapy in late-onset Pompe disease: a systematic literature review

  2013influential citation
• The clinical relevance of outcomes used in late-onset Pompe disease: can we do better?

  2013cites this paper
• International Evaluation of Research and Doctoral Training at the University of Helsinki 2005-2010: RC-Specific Evaluation of BNCTMI - Medical Physics: BNCT & Medical Imaging

  2012cites this paper
• Instability of the DNA repeats mutation in humans hereditary disorders

  2011influential citation